Literature DB >> 22871573

Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Yvonne D Krom1, Julie Dumonceaux, Kamel Mamchaoui, Bianca den Hamer, Virginie Mariot, Elisa Negroni, Linda N Geng, Nicolas Martin, Rabi Tawil, Stephen J Tapscott, Baziel G M van Engelen, Vincent Mouly, Gillian S Butler-Browne, Silvère M van der Maarel.   

Abstract

In most cases facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of the D4Z4 repeat in the 4q subtelomere. This contraction is associated with local chromatin decondensation and derepression of the DUX4 retrogene. Its complex genetic and epigenetic cause and high clinical variability in disease severity complicate investigations on the pathogenic mechanism underlying FSHD. A validated cellular model bypassing the considerable heterogeneity would facilitate mechanistic and therapeutic studies of FSHD. Taking advantage of the high incidence of somatic mosaicism for D4Z4 repeat contraction in de novo FSHD, we have established a clonal myogenic cell model from a mosaic patient. Individual clones are genetically identical except for the size of the D4Z4 repeat array, being either normal or FSHD sized. These clones retain their myogenic characteristics, and D4Z4 contracted clones differ from the noncontracted clones by the bursts of expression of DUX4 in sporadic nuclei, showing that this burst-like phenomenon is a locus-intrinsic feature. Consequently, downstream effects of DUX4 expression can be observed in D4Z4 contracted clones, like differential expression of DUX4 target genes. We also show their participation to in vivo regeneration with immunodeficient mice, further expanding the potential of these clones for mechanistic and therapeutic studies. These cell lines will facilitate pairwise comparisons to identify FSHD-specific differences and are expected to create new opportunities for high-throughput drug screens.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871573      PMCID: PMC3463638          DOI: 10.1016/j.ajpath.2012.07.007

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

2.  FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.

Authors:  T Rijkers; G Deidda; S van Koningsbruggen; M van Geel; R J L F Lemmers; J C T van Deutekom; D Figlewicz; J E Hewitt; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

3.  Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression.

Authors:  R Tupler; L Barbierato; M Memmi; C A Sewry; D De Grandis; P Maraschio; L Tiepolo; A Ferlini
Journal:  J Med Genet       Date:  1998-09       Impact factor: 6.318

4.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

5.  The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes.

Authors:  R Lyle; T J Wright; L N Clark; J E Hewitt
Journal:  Genomics       Date:  1995-08-10       Impact factor: 5.736

6.  Single-cell observations reveal intermediate transcriptional silencing states.

Authors:  Eugenia Y Xu; Karl A Zawadzki; James R Broach
Journal:  Mol Cell       Date:  2006-07-21       Impact factor: 17.970

7.  Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD).

Authors:  Weihua Zeng; Jessica C de Greef; Yen-Yun Chen; Richard Chien; Xiangduo Kong; Heather C Gregson; Sara T Winokur; April Pyle; Keith D Robertson; John A Schmiesing; Virginia E Kimonis; Judit Balog; Rune R Frants; Alexander R Ball; Leslie F Lock; Peter J Donovan; Silvère M van der Maarel; Kyoko Yokomori
Journal:  PLoS Genet       Date:  2009-07-10       Impact factor: 5.917

8.  Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.

Authors:  Patrick W Reed; Andrea M Corse; Neil C Porter; Kevin M Flanigan; Robert J Bloch
Journal:  Exp Neurol       Date:  2007-03-21       Impact factor: 5.330

9.  Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Marielle Wohlgemuth; Kristiaan J van der Gaag; Patrick J van der Vliet; Corrie M M van Teijlingen; Peter de Knijff; George W Padberg; Rune R Frants; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2007-09-07       Impact factor: 11.025

10.  Evolutionary forces shape the human RFPL1,2,3 genes toward a role in neocortex development.

Authors:  Jérôme Bonnefont; Sergey I Nikolaev; Anselme L Perrier; Song Guo; Laetitia Cartier; Silvia Sorce; Térèse Laforge; Laetitia Aubry; Philipp Khaitovich; Marc Peschanski; Stylianos E Antonarakis; Karl-Heinz Krause
Journal:  Am J Hum Genet       Date:  2008-07-24       Impact factor: 11.025

View more
  36 in total

Review 1.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

2.  Dynamic transcriptomic analysis reveals suppression of PGC1α/ERRα drives perturbed myogenesis in facioscapulohumeral muscular dystrophy.

Authors:  Christopher R S Banerji; Maryna Panamarova; Johanna Pruller; Nicolas Figeac; Husam Hebaishi; Efthymios Fidanis; Alka Saxena; Julian Contet; Sabrina Sacconi; Simone Severini; Peter S Zammit
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

3.  The RNA Surveillance Factor UPF1 Represses Myogenesis via Its E3 Ubiquitin Ligase Activity.

Authors:  Qing Feng; Sujatha Jagannathan; Robert K Bradley
Journal:  Mol Cell       Date:  2017-06-29       Impact factor: 17.970

4.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

5.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

6.  The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain.

Authors:  Darko Bosnakovski; Erik A Toso; Lynn M Hartweck; Alessandro Magli; Heather A Lee; Eliza R Thompson; Abhijit Dandapat; Rita C R Perlingeiro; Michael Kyba
Journal:  J Cell Sci       Date:  2017-09-21       Impact factor: 5.285

7.  Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.

Authors:  Amber L Mueller; Andrea O'Neill; Takako I Jones; Anna Llach; Luis Alejandro Rojas; Paraskevi Sakellariou; Guido Stadler; Woodring E Wright; David Eyerman; Peter L Jones; Robert J Bloch
Journal:  Exp Neurol       Date:  2019-07-12       Impact factor: 5.330

8.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

9.  DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Authors:  Vishakha Sharma; Naoe Harafuji; Alexandra Belayew; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors.

Authors:  Naoe Harafuji; Peter Schneiderat; Maggie C Walter; Yi-Wen Chen
Journal:  Orphanet J Rare Dis       Date:  2013-04-05       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.